News from natera, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 09, 2022, 08:33 ET Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology...

Dec 07, 2022, 08:33 ET Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed...

Dec 06, 2022, 05:31 ET Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication in Prenatal Diagnosis of a clinical experience ...

Nov 23, 2022, 08:33 ET Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy,...

Nov 21, 2022, 08:33 ET New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows ...

Nov 15, 2022, 23:01 ET Natera Announces Pricing of Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of...

Nov 15, 2022, 16:30 ET Natera Launches Proposed Follow-On Offering

Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering...

Nov 08, 2022, 16:05 ET Natera Reports Third Quarter 2022 Financial Results

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30,...

Nov 02, 2022, 08:33 ET Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it was awarded a nationwide contract, effective...

Nov 01, 2022, 11:00 ET Natera to Participate in Credit Suisse 31st Annual Healthcare Conference

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy,...

Nov 01, 2022, 08:30 ET Natera to Report its Third Quarter 2022 Results on November 8th

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will release results for its third quarter ended September...

Oct 06, 2022, 08:33 ET New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a manuscript in Gynecologic Oncology, found ...

Oct 04, 2022, 08:33 ET Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta...

Sep 29, 2022, 08:33 ET Natera Announces 2025 ESG Goals with Publication of 2021 Report

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and...

Sep 12, 2022, 09:27 ET Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular...

Sep 06, 2022, 13:32 ET Natera to Participate in Upcoming Investor Conferences

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy,...

Aug 25, 2022, 08:35 ET Natera Earns Great Place to Work Certification™ for Second Consecutive Year

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive...

Aug 11, 2022, 07:32 ET Natera Announces Enrollment Completion for RenaCARE Study

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced full enrollment for the RenaCARE (Renasight Clinical...

Aug 10, 2022, 16:15 ET Natera Announces Q-Sub Filing with FDA for its Panorama® NIPT

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced earlier today at the Canaccord Genuity 42nd Annual Growth Conference ...

Aug 04, 2022, 16:05 ET Natera Reports Second Quarter 2022 Financial Results

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the second quarter ended June 30, 2022...

Aug 01, 2022, 13:13 ET Natera Announces Second Quarter 2022 Earnings Conference Call

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June ...

Jul 18, 2022, 13:35 ET Federal Circuit Rules in Favor of Natera, Upholding Invalidation of CareDx Patents

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, today announced that the Federal Circuit Court of Appeals...

Jul 18, 2022, 08:33 ET Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the CMS...

Jul 14, 2022, 07:33 ET Natera Selected for UnitedHealthcare's Preferred Laboratory Network

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced it has been selected to participate in...

Jun 29, 2022, 11:56 ET Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript in a leading journal...